Intravitreal dexamethasone treatment of bacterial endophthalmitis
ISRCTN | ISRCTN77234772 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN77234772 |
Secondary identifying numbers | OZR-2001-18; NTR189 |
- Submission date
- 20/12/2005
- Registration date
- 20/12/2005
- Last edited
- 05/11/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr J C van Meurs
Scientific
Scientific
Oogziekenhuis Rotterdam
Schiedamsevest 180
Rotterdam
3011 BH
Netherlands
Phone | +31 (0)10 401 7777 |
---|---|
vanMeurs@oogziekenhuis.nl |
Study information
Study design | Randomised, double-blind, placebo controlled, parallel group trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Other |
Study type | Treatment |
Scientific title | |
Study objectives | Intravitreal injection of vancomycin 0.2 mg, gentamycin 0.05 mg, and dexamethasone diphosphate 400 mg reduces tissue damage in patients with bacterial endophthalmitis. |
Ethics approval(s) | Received from the local medical ethics committee |
Health condition(s) or problem(s) studied | Post-operative bacterial endophthalmitis |
Intervention | Intravitreal injection of vancomycin 0.2 mg, gentamycin 0.05 mg, and dexamethasone diphosphate 400 mg or placebo. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Specified |
Drug / device / biological / vaccine name(s) | Vancomycin, gentamycin, dexamethasone diphosphate |
Primary outcome measure | Vision (ETDRS) after 3, 6 and 12 months, panbacterial polymerase chain reaction (PCR). |
Secondary outcome measures | No secondary outcome measures |
Overall study start date | 01/01/2003 |
Completion date | 01/01/2005 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Not Specified |
Sex | Not Specified |
Target number of participants | 150 |
Key inclusion criteria | 1. Post-cataract bacterial endophthalmitis 2. Strong, and increasing, irritation of anterior chamber and/or vitreous during post-operative 8 weeks interval |
Key exclusion criteria | Antibiotics treatment |
Date of first enrolment | 01/01/2003 |
Date of final enrolment | 01/01/2005 |
Locations
Countries of recruitment
- Netherlands
Study participating centre
Oogziekenhuis Rotterdam
Rotterdam
3011 BH
Netherlands
3011 BH
Netherlands
Sponsor information
Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) (The Netherlands)
Hospital/treatment centre
Hospital/treatment centre
Schiedamsevest 180
Rotterdam
3011 BH
Netherlands
Phone | +31 (0)10 401 77 77 |
---|---|
info@oogziekenhuis.nl | |
https://ror.org/02hjc7j46 |
Funders
Funder type
Research organisation
Foundation of Scientific Research at the Eye Hospital (Stichting Wetenschappelijk Onderzoek het Oogziekenhuis) (The Netherlands)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |